Full Antagonism of the Estrogen Receptor without a Prototypical Ligand Side Chain

Resistance to endocrine therapies remains a significant clinical problem for estrogen receptor-α (ERα)-positive breast cancer. On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies. Here we present a full-antagonist ligand serie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Chem Biol
Main Authors: Srinivasan, Sathish, Nwachukwu, Jerome C., Bruno, Nelson E., Dharmarajan, Venkatasubramanian, Goswami, Devrishi, Kastrati, Irida, Novick, Scott, Nowak, Jason, Cavett, Valerie, Zhou, Hai-Bing, Boonmuen, Nittaya, Zhao, Yuechao, Min, Jian, Frasor, Jonna, Katzenellenbogen, Benita S., Griffin, Patrick R., Katzenellenbogen, John A., Nettles, Kendall W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161551/
https://ncbi.nlm.nih.gov/pubmed/27870835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nchembio.2236
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados